# Soliqua 100/33

NDC: 0024-5761
Generic name: insulin glargine and lixisenatide
Labeler / Manufacturer: Sanofi-Aventis U.S. LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20161121

FDA application: BLA208673

## Active ingredients

- INSULIN GLARGINE: 100 U/mL
- LIXISENATIDE: 33 ug/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0024-5761"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0024-5761
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc